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Abstract 1 
Sulforaphane is a naturally-occurring isothiocyanate with promising chemopreventive 2 
activity. An analytical method, utilising LC-MS/MS, that allows the determination of 3 
sulforaphane in small volumes of rat plasma following exposure to low dietary doses 4 
was developed and validated, and employed to determine its absolute bioavailability 5 
and pharmacokinetic characteristics. Rats were treated with either a single intravenous 6 
dose of sulforaphane (2.8 μmol/kg) or single oral doses of 2.8, 5.6 and 28 μmol/kg.  7 
Sulforaphane plasma concentrations were determined in blood samples withdrawn 8 
from the rat tail at regular time intervals. Following intravenous administration, the 9 
plasma profile of sulforaphane was best described by a two-compartment 10 
pharmacokinetic model, with a prolonged terminal phase. Sulforaphane was very well 11 
and rapidly absorbed, and displayed an absolute bioavailabilty of 82% which, 12 
however, decreased at the higher doses, indicating a dose-dependent pharmacokinetic 13 
behaviour; similarly, Cmax values did not rise proportionately to the dose. At the 14 
highest dose used, the rate of absorption constant kab, biological half-life t1/2 and 15 
apparent volume of distribution decreased significantly. It is concluded that in the rat 16 
orally administered sulforaphane is rapidly absorbed, achieving high absolute 17 
bioavailability at low dietary doses, but dose-dependent pharmacokinetics was 18 
evident, with bioavailability decreasing with increasing dose.  19 
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Introduction   1 
Isothiocyanates are promising chemopreventive agents that are present in substantial 2 
concentrations in brassica cruciferous vegetables; in epidemiological studies intake of 3 
these vegetables was found to afford protection against a number of cancers1-3. 4 
Isothiocyanates occur as glucosinolates but are released following exposure to the 5 
enzyme myrosinase (β-thioglucoside glucohydrolase) which comes into contact with 6 
these compounds during the harvesting, chopping and mastication of these vegetables. 7 
Moreover, microbial myrosinase activity in the human intestine contributes to the 8 
release of isothiocyanates from their glucosinolate precursors4. 9 
 Epidemiological studies revealed the potential of isothiocyanates to protect 10 
against tumourigenesis at a number of sites5,6. Furthermore, studies conducted in 11 
animal models established that isothiocyanates can antagonise the carcinogenicity of 12 
chemicals, including dietary carcinogens such as polycyclic aromatic hydrocarbons7. 13 
A number of mechanisms appear to contribute to their anticarcinogenic activity 14 
including impairment of the bioactivation of carcinogens and increased detoxication 15 
of their reactive intermediates, suppressed cellular proliferation and increased 16 
apoptosis3,8-10. As most of these mechanistic studies have been conducted in in vitro 17 
systems, utilising a range of concentrations, in order to extrapolate such data to the in 18 
vivo situation it is essential that the pharmacokinetic fate of isothiocyanates, following 19 
dietary levels of intake, including their bioavailability and plasma concentrations are 20 
ascertained. 21 
 One such isothiocyanate is sulforaphane [1-isothiocyanato-4-22 
(methylsulphinyl) butane], found particularly in broccoli where it is present as the 23 
glucosinolate, glucoraphanin. In animal studies it efficiently antagonised the 24 
carcinogenicity of polycyclic aromatic hydrocarbons11 and reduced the number of 25 
azoxymethane-induced aberrant crypt foci in rat colon12. Although its mechanism of 26 
action appears to be multifactorial, its chemopreventive effect also involves 27 
impairment of the initiation stage of carcinogenesis. Sulforaphane inhibited the DNA 28 
binding of benzo[a]pyrene and 1,6-dinitropyrene in human mammary epithelial cells13  29 
and the formation of DNA adducts with the heterocyclic amine 2-amino-1-methyl-6-30 
phenylimidazo[4,5-b]pyridine (PhIP) in human hepatocytes14. Even when 31 
administered at dietary doses, sulforaphane stimulates detoxication enzymes such as 32 
quinone reductase15, and at higher doses it also enhances the activity of other 33 
deactivating enzyme systems such as glutathione S-transferase11,16. However, 34 
 4
sulforaphane also acts at the post-initiation stages, for example suppressing the 1 
conversion of lung benign tumours to carcinomas in mice17. An interesting 2 
observation is that mercapturates, the principal metabolites of isothiocyanates, may 3 
retain the anticarcinogenic activity of the parent compounds17,18. 4 
 In the present study an LC-MS/MS method has been developed to determine 5 
sulforaphane in rat plasma, and was used to determine the absolute bioavailability of 6 
dietary doses of sulforaphane following oral and intravenous administration.  7 
 8 
Experimental methods 9 
 10 
Materials  11 
R,S-Sulforaphane was purchased from LKT Laboratories (St Paul, Minnesota, USA). 12 
All solvents were of HPLC grade (Fisher scientific, UK).    13 
 14 
Treatment of animals 15 
Male Wistar albino rats (200g) were obtained from B&K Universal Ltd (Hull, East 16 
Yorkshire, UK). The animals were housed at 22 ± 2 °C, 30-40 % relative humidity in 17 
an alternating 12-hr light:dark cycle with light onset at 07.00 hr. The animals were 18 
allowed to acclimatise for at least 4 days before commencement of the study; they 19 
were then treated, 4 per group, with either a single intravenous dose of sulforaphane 20 
(0.5 mg/kg), in a volume of 100 μl of water, or single oral doses of 0.5, 1.0 and 5.0 21 
mg/kg, corresponding to 2.8, 5.6 and 28 μmol/kg, dissolved in 1 ml of water.  Blood 22 
samples (100 μl) were withdrawn from the rat tail at regular time intervals for 8 hours, 23 
and placed into lithium-heparinised centrifuge tubes. A sample was also obtained 24 24 
hours after administration as well as from untreated rats.  25 
 26 
Sample preparation 27 
Aliquots of the plasma (40 μl) were made to 1 ml with 0.01 M phosphate-buffered 28 
saline (pH 7.3) and were subsequently extracted with chloroform (5 ml) twice for 30 29 
minutes; the layers were separated by centrifugation at 510g for 10 minutes. The 30 
combined chloroform extracts were evaporated under nitrogen using an N-EVAP® 31 
model 111 (Organomation Assoc. Inc, USA) and redissolved in 40 μl of the HPLC 32 
mobile phase (10 % acetonitrile in water containing 0.1% formic acid), and 20 μl was 33 
 5
injected for analysis. Quality control sulforaphane solutions of known concentrations 1 
(0.05, 0.5 and 1.8 μg/ml) were carried through the same procedure. 2 
 3 
Determination of sulforaphane in rat plasma 4 
Plasma concentrations of sulforaphane in the rat plasma were determined by LC-5 
MS/MS, using methodology developed in our laboratories. Separation of sulforaphane 6 
was achieved using an Ultimate 3000 (Dionex, Camberley, UK) HPLC employing a 7 
Synergi 4u  Fusion-RP analytical column (80Å particle size, 150 x 1 mm) fitted with a 8 
KrudKatcher in-line filter, both supplied by Phenomenex (Macclesfield, UK). Mobile 9 
phase consisted of solvent A (10 % acetonitrile in water containing 0.1% formic acid) 10 
and solvent B (90 % acetonitrile in water containing 0.1% formic acid). The analyte 11 
was eluted with a linear gradient (0 to 20%) of organic solvent B over 22 min. The 12 
column was then washed with 80% of solvent B over 3 min and re-equilibrated for a 13 
further 10 min; the eluent flow rate was 0.05 ml/min. Under these conditions, the 14 
retention time of sulforaphane was about 18 minutes in a total run time 35 minutes. 15 
 Sulforaphane was detected on-line using a API 2000 triple quadrupole mass 16 
spectrometer (Applied Biosystems, Warrington, UK) equipped with a turbo-ion 17 
electrospray probe, operating in the positive ionisation mode. The analyte was 18 
detected by monitoring the m/z 178→ 114 and 178→72 mass transition (Figure 1) in 19 
the MRM scan mode, under the following conditions: turbo ion-spray interface 20 
temperature, 350°C; collision-activated dissociation gas pressure and  curtain gas 21 
pressure, 3 and 40 p.s.i. respectively; turbo ion-spray voltage, 5000 V; declustering, 22 
entrance and focusing potential, 11, 10 and 300 V respectively; collision energy 18 23 
and 41 V for m/z 114 and 72 transitions respectively; collision cell exit potential, 15 24 
V. Acquisition of data was achieved using the Analyst software (version 1.4; Applied 25 
Biosystems).  26 
 27 
Pharmacokinetic analysis 28 
Pharmacokinetic analysis was carried out using PK solutionsTM software package 29 
(version 2.0, Summit Research Services, Ohio, USA). Because of the very long 30 
terminal phase (t1/2 = 65.6 hours after intravenous administration), pharmacokinetic 31 
parameters were calculated from the better defined AUC0-24 , rather than from AUC0-, 32 
to avoid introducing an inaccuracy in extrapolating the terminal phase to time infinity. 33 
 6
AUC0-24 was calculated using the trapezoidal rule utilising the time data determined 1 
experimentally. Absolute bioavailability (F) was determined from the ratio of the oral 2 
to intravenous dose-normalised AUC0-24 values. Apparent volume of distribution (Vd) 3 
was calculated from the equation Vd = FD/ AUC0-24 kel, where kel is the elimination 4 
rate constant. Plasma clearance (Cl) was determined using the equation Cl = FD/ 5 
AUC0-24. Finally, Cmax and Tmax were determined graphically from the plasma 6 
concentration versus time plots. 7 
Animal data were analysed individually, and are presented as mean  SD; 8 
statistical evaluation was performed using the Student’s t-test, where n=4. 9 
 10 
Results 11 
A LC-MS/MS method for the measurement of sulforaphane in rat plasma has been 12 
developed and validated. No sulforaphane was detected in rat plasma prior to 13 
administration of the isothiocyanate. Limit of detection, defined as the lowest 14 
concentration of analyte that generates a minimum signal to noise ratio of 3, and limit 15 
of quantification, defined as the lowest concentration of analyte that gives rise to an 16 
instrument response with a minimum signal to noise ratio of 5, were 5 and 15 ng/ml 17 
respectively, following a 20 μl injection (Figures 2A and 2B). The calibration curve, 18 
at a plasma concentration range of 0.01 to 2 μg/ml showed excellent linear 19 
relationship, with an R value of 0.99. Recovery of sulforaphane at three plasma 20 
concentrations, 0.05, 0.5 and 1.8 μg/ml, was 91, 91 and 88% respectively (n=6). At 21 
the same concentrations inter-assay variation was 1.0, 2.2 and 3.2% respectively, 22 
whereas intra-assay variation, established at the same concentrations, was 1.5, 6.5 and 23 
5% respectively (n=4). Finally, accuracy was established by comparing calculated and 24 
theoretical values at two plasma concentrations (0.5 and 1.8 μg/ml); calculated and 25 
theoretical values did not differ more than 11 % (n=4). 26 
Figure 3 shows the time-course changes in the plasma concentrations of 27 
sulforaphane, plotted using a semi logarithmic plot, following intravenous 28 
administration to rats; the plasma profile is best described by a two-compartment 29 
pharmacokinetic model. Within two hours, plasma concentrations decline to about 30 
10% of the levels present 0.5 hour after administration; the concentrations then remain 31 
fairly constant indicating a long terminal phase. Similarly, following oral 32 
administration of the same dose, a marked and rapid decline in plasma concentrations 33 
 7
of sulforaphane is evident between 1 hour after administration, when peak 1 
concentrations are achieved, and 2 hours after administration, followed by a 2 
prolonged terminal phase (Figure 3). At the higher doses, however, the decline in 3 
plasma concentrations, after maxima have been attained, is more gradual.  4 
 The pharmacokinetic parameters of sulforaphane following oral and 5 
intravenous administration are shown in table 1. The Cmax and AUC0-24 values in 6 
orally-treated rats increased with dose, but not proportionately; rise in AUC0-24  and 7 
Cmax values was lower than would be anticipated. Comparison of AUT0-24 values 8 
between the intravenously- and orally-treated groups, at the 0.5 mg/kg dose, indicate 9 
an absolute bioavailabilty of 82% which, however, decreased at the higher doses. 10 
Finally, the rate of absorption constant kab, biological half-life t1/2 and apparent 11 
volume of distribution decreased at the highest dose used.  12 
 13 
Discussion  14 
An analytical method, utilising LC-MS/MS, that allows the determination of 15 
sulforaphane in small volumes of rat plasma following exposure to low dietary doses 16 
was developed and validated, and employed to determine its absolute bioavailability 17 
and pharmacokinetic characteristics in the rat following intravenous and oral 18 
administration. An 150g serving of fresh broccoli will release 56-112 mg of 19 
sulforaphane19, so that the intake for a 70 kg individual would be 0.8-1.6 mg/kg. The 20 
doses employed in this study of 0.5-5.0 mg/kg were chosen to represent such 21 
concentrations of intake. 22 
 In the current studies it was considered prudent not to deprive the animals of 23 
food prior to administration of sulforaphane, as it could have an impact on its 24 
metabolic clearance. The principal pathway of metabolism of this compound involves 25 
conjugation with glutathione, followed by further processing of the conjugate to the 26 
mercapturate20. Withdrawal of food can result in a decline in the cellular 27 
concentrations of glutathione21. 28 
 Following oral administration, sulforaphane peak plasma concentrations were 29 
attained at about one hour, indicating rapid absorption, compatible with its 30 
lipophilicity and small molecular size. Similarly, in studies conducted in human 31 
volunteers, isothiocyanates, measured as total dithiocarbamates, were rapidly 32 
absorbed reaching peak plasma concentrationss one hour after ingestion of broccoli 33 
sprout preparations22. In a recent study, where sulforaphane levels were determined in 34 
 8
volunteers consuming a broccoli soup, maxima were attained one hour after intake, in 1 
concordance with the present findings in rats23. At the highest dose only, the 2 
absorption rate constant decreased, and this may explain in part the fact that Cmax 3 
values did not rise proportionately to the dose. This observation raises the possibility 4 
that sulforaphane may to some extent be absorbed by a carrier-mediated transport 5 
mechanism that is saturated at this dose level. 6 
Oral absolute bioavailability of sulforaphane in rats was over 80% at the 7 
lowest oral dose studied. It is likely that sulforaphane is subjected to modest first-pass 8 
metabolism as glutathione and mercapturate metabolites of this isothiocyanate can be 9 
generated by intestinal as well as hepatic enzymes, or even possibly in the blood as it 10 
contains low concentrations of glutathione that can interact chemically with the 11 
isothiocyanate. Studies using human jejunum in situ have established that 12 
sulforaphane is well absorbed by enterocytes where it is conjugated with glutathione 13 
during absorption and secreted back into the lumen24. 14 
In the present study, the oral bioavailability of sulforaphane was dose-15 
dependent, being only about 20% at the highest dose studied of 28 μmol/kg, i.e. a 16 
quarter of that observed at a dose of 2.8 μmol/kg. These observations imply that 17 
intake of sulforaphane supplements may not be as effective as envisaged in achieving 18 
high plasma concentrations of the compound.  Isothiocyanates display high protein 19 
binding25,26, presumably because of their facile interaction with –SH groups, and it is 20 
conceivable that at the higher doses protein-binding sites are saturated so that 21 
sulforaphane remains free and available for metabolism and excretion. It is relevant to 22 
point out that albumin contains only a single residue of free cysteine (Cys34).  The 23 
observed dose-dependent decrease in biological half-life values concord with such a 24 
mechanism of action. Non-linear pharmacokinetics in rats have also been reported for 25 
phenethyl isothiocyanate, having an aromatic substituent25, and collectively these 26 
observations indicate that the isothiocyanate group is more likely to be responsible for 27 
this effect rather than the substituent. 28 
Following intravenous and oral dosing a rapid marked drop is observed in the 29 
plasma concentrations of sulforaphane, and this most likely reflects cellular uptake. 30 
Isothiocyanates such as sulforaphane, attain very high intracellular concentrations as a 31 
result of their interaction with glutathione16,27,28. As the absorbed sulforaphane is 32 
readily conjugated with glutathione and possibly other thiols, the concentration 33 
gradient drives the further cellular uptake of the isothiocyanate, which can achieve 34 
 9
mM concentrations, and is accompanied by a marked drop in glutathione levels17. The 1 
glutathione and cysteinylglycine conjugates are exported through membrane 2 
transporters such as P-glycoprotein29,30. It has been demonstrated in in vitro studies 3 
that peak intracellular concentrations of isothiocyanates are attained within 3 hours of 4 
exposure, and intracellular concentration may be as much as 200-fold higher than 5 
extracellular concentration3. Such extensive intracellular localisation would explain 6 
the large apparent volume of distribution. Elimination of sulforaphane was 7 
characterised by a long terminal phase; in fact, no major difference was evident in 8 
plasma concentrations between 6 and 24 hours following intravenous administration 9 
or oral administration at the lower doses. Most likely this is a consequence of protein 10 
binding, rendering the isothiocyanate unavailable for elimination through metabolism 11 
and excretion. 12 
 In summary, the present paper demonstrates that in the rat, following oral 13 
administration of dietary doses, sulforaphane is rapidly absorbed, achieving high 14 
absolute bioavailability at low doses.  However, dose-dependent pharmacokinetics 15 
was evident, with bioavailability decreasing with increasing dosage. 16 
 17 
 18 
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Table 1: Absolute bioavailability and pharmacokinetic parameters of 8 
sulforaphane following administration of dietary doses 9 
 10 
Results are presented as Mean ± SD for four animals. 11 
*P<0.05; **P<0.01; ***P<0.001, when compared to the 0.5 mg/kg oral dose 12 
 13 
   14 
Parameter Intravenous  
(0.5 mg/kg) 
Oral  
(0.5 mg/kg) 
Oral  
(1.0 mg/kg) 
Oral  
(5.0 mg/kg) 
Cmax (ng/ml) - 46.4 ± 19.4 84.0 ± 19.6* 211.3 ± 24.3*** 
Tmax (h) - 0.5 ± 0.0 0.8 ± 0.3 1.0 ± 0.7 
kab (h-1) - 5.78 ± 1.70 3.74 ± 0.44 2.57 ± 1.36* 
kel (h-1) 0.011 ± 0.003 0.012 ± 0.002 0.015 ± 0.005 0.028 ± 0.009* 
t1/2 (h) 65.6 ± 16.3 62.2 ± 20.07 50.5 ± 16.0 27.3 ± 10.8** 
Clp (ml/h) 265 ± 28 264 ± 18 260 ± 28 263 ± 10 
Vd (l/kg) 102 ± 33 95 ± 23 77 ± 30 42 ± 18* 
AUC0-24  
(ng ml-1 h) 
476 ± 46 392 ± 26 493 ± 69* 1001 ± 37*** 
F % 100 82.4 ± 5.3 51.8 ± 7.2*** 21.0 ± 0.8*** 
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Legends to figures 1 
 2 
Figure 1: Structure of sulforaphane transitions monitored in the MRM mode 3 
 4 
Figure 2: Determination of sulforaphane in rat plasma 5 
 6 
A. Representative chromatogram of sulforaphane in spiked plasma extracts at the 7 
limit of detection; B. Representative chromatogram of sulforaphane in spiked plasma 8 
extracts at the limit of quantification. The outer peak is the more abundant m/z 178 to 9 
114 transition whereas the inner peak represents that of m/z 114 to 72. 10 
CPS, counts per second 11 
  12 
 13 
Figure 3: Plasma concentration vs time curves in rats following oral and 14 
intravenous exposure to sulforaphane 15 
 16 
Blood samples were withdrawn 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after 17 
administration. Bars represent SD values where n=4 18 
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